Logo image of ACTU

ACTUATE THERAPEUTICS INC (ACTU) Stock Fundamental Analysis

USA - NASDAQ:ACTU - US0050831009 - Common Stock

6.89 USD
+0.24 (+3.61%)
Last: 9/26/2025, 8:00:00 PM
Fundamental Rating

0

Overall ACTU gets a fundamental rating of 0 out of 10. We evaluated ACTU against 538 industry peers in the Biotechnology industry. ACTU has a bad profitability rating. Also its financial health evaluation is rather negative. ACTU has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ACTU has reported negative net income.
In the past year ACTU has reported a negative cash flow from operations.
ACTU Yearly Net Income VS EBIT VS OCF VS FCFACTU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of ACTU (-354.20%) is worse than 94.61% of its industry peers.
Industry RankSector Rank
ROA -354.2%
ROE N/A
ROIC N/A
ROA(3y)-405.72%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACTU Yearly ROA, ROE, ROICACTU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -5K -10K -15K -20K -25K

1.3 Margins

ACTU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACTU Yearly Profit, Operating, Gross MarginsACTU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

ACTU has more shares outstanding than it did 1 year ago.
ACTU has a better debt/assets ratio than last year.
ACTU Yearly Shares OutstandingACTU Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M
ACTU Yearly Total Debt VS Total AssetsACTU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

ACTU has an Altman-Z score of -31.49. This is a bad value and indicates that ACTU is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ACTU (-31.49) is worse than 89.78% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -31.49
ROIC/WACCN/A
WACCN/A
ACTU Yearly LT Debt VS Equity VS FCFACTU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 0.73 indicates that ACTU may have some problems paying its short term obligations.
ACTU has a Current ratio of 0.73. This is amonst the worse of the industry: ACTU underperforms 91.64% of its industry peers.
ACTU has a Quick Ratio of 0.73. This is a bad value and indicates that ACTU is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.73, ACTU is doing worse than 90.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.73
Quick Ratio 0.73
ACTU Yearly Current Assets VS Current LiabilitesACTU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

ACTU shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.53%.
EPS 1Y (TTM)-8.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ACTU is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.50% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y64.14%
EPS Next 2Y25.83%
EPS Next 3Y13.5%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACTU Yearly Revenue VS EstimatesACTU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 1M 2M 3M 4M
ACTU Yearly EPS VS EstimatesACTU Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACTU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACTU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACTU Price Earnings VS Forward Price EarningsACTU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACTU Per share dataACTU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

ACTU's earnings are expected to grow with 13.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.83%
EPS Next 3Y13.5%

More info and screens

0

5. Dividend

5.1 Amount

ACTU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACTUATE THERAPEUTICS INC

NASDAQ:ACTU (9/26/2025, 8:00:00 PM)

6.89

+0.24 (+3.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-13 2025-11-13
Inst Owners54.07%
Inst Owner Change7.15%
Ins Owners4.8%
Ins Owner Change0%
Market Cap157.92M
Analysts82
Price Target27.29 (296.08%)
Short Float %2.87%
Short Ratio6.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.04%
Min EPS beat(2)-3.43%
Max EPS beat(2)3.52%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.76%
PT rev (3m)13.03%
EPS NQ rev (1m)-2.78%
EPS NQ rev (3m)7.5%
EPS NY rev (1m)0%
EPS NY rev (3m)0.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.99
OCFYN/A
SpS0
BVpS-0.12
TBVpS-0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -354.2%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-405.72%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.73
Quick Ratio 0.73
Altman-Z -31.49
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.94%
EPS Next Y64.14%
EPS Next 2Y25.83%
EPS Next 3Y13.5%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.01%
OCF growth 3YN/A
OCF growth 5YN/A